Abstract

ADVANCEMENT IN BIOMARKERS FOR SCHIZOPHRENIA THERANOSTIC: A REVIEW

Harsh Thakkar, Amit Khairnar, Monika Sharma, Rajeshwari Rathod*

ABSTRACT

Schizophrenia is a neurodevelopmental disorder and is non dividing line between reality and imagination. Though schizophrenia is multidimensional disease, there is no single convincible biomarker available for the disease. Diagnosis of schizophrenia at early stage is the most challenging task and due to misdiagnosis there are severe clinical threatening implications. Identification of biomarker is needed to diagnose or determine the response of the treatment in people with Schizophrenia. Biomarker research involves diagnostic, prognostic and theranostics approach and for that appropriate methodological strategy is required. Highly acknowledged pathophysiology and treatment approaches involved in schizophrenia associated with neurotransmitter changes, like dopamine and serotonin, though disorder cannot be prevented. Other than neurotransmitter changes, omics based approach is also most widely used. In this review, we will discuss some modernistic techniques like genomics, metabolomic, neuroinflammation based along with some symptomatic based biomarkers which could unwind new direction of biomarker research with clinical applicability. The combinatorial discovery approach will provide easy diagnosis, severity of disease and treatment outcomes without precipitating offshoots.

Keywords: Schizophrenia, Biomarkers, Metablomics, Genomics, Combinatorial discovery.